Sign in

CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
813879991
Phone
617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Planned sale Chief Scientific Officer sold 4,000 shares at $12.36 ($49,440)
  2. 4 Planned sale Chief Scientific Officer sold 8,000 shares at $21.57 ($172,560)
  3. 4 Planned sale Chief Scientific Officer sold 30,000 shares at $20.26 ($607,800)
  4. 4 Planned sale Chief Scientific Officer sold 8,000 shares at $17.82 ($142,560)
  5. 4 Grant or award Chief Legal Officer acquired 2,470 shares (grant or award)
  6. 4 Grant or award Chief Financial Officer acquired 1,541 shares (grant or award)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Planned sale Chief Scientific Officer sold 8,000 shares at an average $14.62 ($116,996)
  14. 4 Planned sale Chief Scientific Officer sold 8,000 shares at $15.68 ($125,440)
  15. 4 Planned sale Chief Scientific Officer sold 1,780 shares at $14.14 ($25,169)
  16. 4 Planned sale Chief Scientific Officer sold 5,353 shares at an average $14.31 ($76,617)
  17. 4 Open-market sale President and CEO sold 13,515 shares at $14.47 ($195,562)
  18. 4 Open-market sale Chief Medical Officer sold 4,582 shares at $14.47 ($66,302)
  19. 4 Open-market sale Chief Legal Officer sold 3,601 shares at $14.47 ($52,106)
  20. 4 Open-market sale Chief Medical Officer sold 4,982 shares at $13.62 ($67,855)

Page 1 of 13 · 253 filings